Hodgkin’s lymphoma transformation of CLL/SLL: case report and review of the literature

Seda Gün1*, Memiş Hilmi Atay2, Mehmet Turgut2 and Levent Yildiz1

1Department of Pathology, Ondokuz Mayis University, Medical School, Turkey
2Department of Hematology, Ondokuz Mayis University, Medical School, Turkey

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are low-grade lymphoproliferative disorders of mature B lymphocytes characterized by lymphocytosis. About 3-15% of the cases transform into a more aggressive lymphoid malignancy. This transformation is known as Richter Syndrome (RS) [1-3]. CLL/SLL progression is mostly observed as prolymphocytes or immunoblasts, Hodgkin’s lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), T-cell non-Hodgkin’s lymphoma, multiple myeloma, Burkitt’s lymphoma and rarely as B-lymphoblastic lymphoma/leukemia (B-ALL) [1,4,5].

With its morphological and immunohistochemical features, Hodgkin’s variant of Richter’s syndrome, to be more precise, the transformation of CLL/SLL into Hodgkin’s lymphoma is similar to classical HL [6]. The patients receive aggressive treatment, and they have poor prognosis [2]. We would like to present a rare case of Hodgkin’s lymphoma transformation of CLL/SLL with the review of literature.

Introduction

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are low-grade lymphoproliferative disorders of mature B lymphocytes characterized by lymphocytosis. About 3-15% of the cases transform into a more aggressive lymphoid malignancy. This transformation is known as Richter Syndrome (RS) [1-3]. CLL/SLL progression is mostly observed as prolymphocytes or immunoblasts, Hodgkin’s lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), T-cell non-Hodgkin’s lymphoma, multiple myeloma, Burkitt’s lymphoma and rarely as B-lymphoblastic lymphoma/leukemia (B-ALL) [1,4,5].

With its morphological and immunohistochemical features, Hodgkin’s variant of Richter’s syndrome, to be more precise, the transformation of CLL/SLL into Hodgkin’s lymphoma is similar to classical HL [6]. The patients receive aggressive treatment, and they have poor prognosis [2]. We would like to present a rare case of Hodgkin’s lymphoma transformation of CLL/SLL with the review of literature.

Case history

The 69-year-old male patient was admitted to Department of Hematology with the complaints of fatigue and weakness. The patient did not have any complaints of night sweat, fever or weight loss. Facial pallor, splenomegaly and lymph node enlargements in the neck and inguinal region were observed in the physical examination. The largest of the lymph nodes was 2x1 cm. His hemogram revealed leukocytosis, and 80% mature lymphocytes and “smudge” cells were observed in the peripheral blood smear. In 2011, bone marrow aspiration and bone marrow biopsy were performed with CLL/SLL prediagnosis. In flow cytometry, CD5, CD20 and CD23 were 69%, 92% and 63% respectively. Bone marrow biopsy sample revealed lymphoid cells that diffusely infiltrated the bone marrow. They had monotonous, small, condensed chromatin and stained positive for CD20 (Clone L26, BioSB), CD79a (JCB 117, Bio SB), bcl2 (Clone bcl-2/100/D5, Leica) and CD23 (Clone SP23, Thermo) in the immunohistochemical study (Figure 2). These cells stained positive for CD30 (Clone RBT-CD5, BioSB) and CD 15 (SPM 119, BioSB) but negative for CD20(Clone L26, BioSB) (Figure 4).

Depending on the morphological and immunophenotypic findings, Hodgkin’s lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma diagnosis was made. The patient died due to respiratory and cardiac arrest while he was being treated in the intensive care unit with the diagnoses of hypervolemia and pneumonia.

In the histopathological examination of the lymph node, the lymph node exhibited a diffuse infiltrate of lymphoid cells with monotonous small-medium-sized condensed chromatin (Figure 1). These cells stained positive for CD20 (Clone L26, BioSB), CD79a (JCB 117, Bio SB), PAX5 (Cat.No.RB-9406-p, Thermo), CD5 (Clone 1G12, Leica), bcl2 (Clone bcl-2/100/D5, Leica) and CD23 (Clone SP23, Thermo) in the immunohistochemical study (Figure 2). In the focuses outside CLL/SLL areas, large Hodgkin and Reed-Sternberg (H-RS) cells with prominent nucleoli were observed in inflammatory background composed of heterogeneous cell population of rare eosinophils, plasma cells and fibrohistiocytic cells (Figure 3). These cells stained positive for CD30 (Clone RBT-CD5, BioSB) and CD 15 (SPM 119, BioSB) but negative for CD20(Clone L26, BioSB) (Figure 4).

Figure 1. Lymph node with a diffuse population of small monomorphous CLL/SLL (HEX200).

Correspondence to: Seda Gün, Department of Pathology, Ondokuz Mayis University, Medical School, Kurupelit 55139 Samsun, Turkey, E-mail: seda.gun@omu.edu.tr

Received: August 20, 2017; Accepted: September 26, 2017; Published: September 28, 2017
Discussion

Richter's syndrome was first described by Maurice N. Richter in 1928 in a patient with rapidly fatal and diffusive lymphadenopathy and hepatosplenomegaly associated with CLL/SLL [7]. Later, other lymphoid malignancies such as prolymphocytic leukemia, HL, lymphoblastic lymphoma and "hairy cell" leukemia have also been reported in CLL/SLL patients [8]. Furthermore, it has been reported that the development frequency of secondary cancers such as basal cell carcinoma, squamous cell carcinoma, breast cancer, prostate cancer or malignant melanoma is higher in these patients [1,6].

In the studies in literature, HL transformation is encountered in the 0.4% of the CLL/SLL patients [6,8]. Bockorny et al. identified 86 cases in the literature between 1975 and 2011, including the series of Tsimberideou et al. [4]. Ages, HL transformation times and survivals of the CLL/SLL patients reported in the literature up to the date are given in Table 1. The mean HL transformation time of CLL/SLL in the series of Tsimberideou et al. was 4.6 years [6]. The patients are mostly elderly males diagnosed with the B-symptoms; lymphadenopathy and hepatosplenomegaly [1,8]. In our case, the patient was in the 7th decade, and he had lymphadenopathy and splenomegaly both in the initial symptoms and in the recurrence.

Etiopathogenesis of the disease is not fully known. EBV infection has been identified in some patients. Additionally, it has been argued that immunosuppressive therapy, especially fludarabine, may increase the risk of transformation. It has been considered that elongated and significant reduction of CD4+ and CD8+ T lymphocytes in EBV-positive B cells due to proliferation and accumulation may cause the development of a high-grade lymphoma [1,4,8].

Two morphological types of Hodgkin's lymphoma transformation of CLL/SLL have been identified. Type 1 is characterized by H-RS cells scattered over a surface containing CLL cells. In Type 2, H-RS cells are separate from the CLL cells in a typical polymorphic inflammatory cells background. It has been argued that Type 1 transformation occurs due to the progression of the underlying CLL cells - especially when the H-RS cells expresses the B cell markers and Type 2 develops as 2 different disorders [1,8]. The origin of H-RS cells encountered in Type 2 is different from that of CLL cells. In three of the four patients with Hodgkin's lymphoma transformation of CLL/SLL, the relation between the clones of CLL and H-RS cells has been identified by using DNA sequencing and polymerase chain reaction (PCR) [3,4,8]. On the other hand, clone has also been reported in unrelated cases, and EBV and chemotherapy are supposed to play a significant role in the development of the disease [4]. In our case, CLL/SLL and Hodgkin's cells were observed separately in the histopathological study, and H-RS cells were not stained with B-cell markers. Thus, morphologically and immunohistochemically, it was considered to be Type 2.

As in our case, the most common histological subtype encountered in the literature is the mixed cellular type. It is followed by nodular sclerosing, lymphocyte-poor and lymphocyte rich types [1,4].

The most effective treatment is not known yet. HL-targeted, multiple chemotherapy protocols are employed. In general, the response to the treatment and clinical course are poor [1,4,6].

Hodgkin's transformation of CLL/SLL is a rare disorder with a poor clinical course and requires different treatment approaches. Its definitive diagnosis is made with histopathological study. Molecular genetic studies have a significant role in understanding its etiopathogenesis, which will make the development of specific treatments for the disease.
possible. When a disease progression in follow-up patients with CLL/SLL is identified clinically, histopathological evaluation of the diagnosis is significant to detect the possible comorbid transformations. It is emphasized through this case that in patients with the above-mentioned clinical features, the transformation may occur not only towards the B-cell lymphomas but also towards the leukemias or Hodgkin’s disease.

References